ArticleHaematologica2021
Molecular attributes underlying central nervous system and systemic relapse in diffuse large B-cell lymphoma.
Article in Haematologica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Trial
- Clinical outcomes, patterns of relapse, and molecular landscape of advanced stage high-grade B-cell lymphoma.Blood advances · 2026Article
- Clinical, Biological, and Treatment-Related Predictors of Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma: A Retrospective Cohort Study.Journal of clinical medicine · 2026Article
- Glycolysis-Driven Immune Subtypes in the Tumor Microenvironment Determine Clinical Outcomes in Diffuse Large B-Cell Lymphoma.Cancers · 2025Article
- Impact of MYD88 and/or CD79B mutations on central nervous system relapse in patients with diffuse large B-cell lymphoma.British journal of haematology · 2025Article
- Clonal evolution defines risk stratification for central nervous system leukemia in adult acute lymphoblastic leukemia.Annals of hematology · 2024Article
- Systemic diffuse large B-cell lymphoma involving the central nervous system has high rates of defective antigen presentation and immune surveillance.Haematologica · 2024Article
- Review
- In-depth characterization of intratumoral heterogeneity in refractory B-cell non-Hodgkin lymphoma through the lens of a Research Autopsy Program.Haematologica · 2023Article
- SOHO State of the Art Updates and Next Questions: Prophylaxis and Management of Secondary CNS Lymphoma.Clinical lymphoma, myeloma & leukemia · 2022Review
- Molecular Genetics of Relapsed Diffuse Large B-Cell Lymphoma: Insight into Mechanisms of Therapy Resistance.Cancers · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.